Scale-up company Hedera secures EUR 15 million in growth funding for new cancer diagnostics solution
Health tech company Hedera DX – with Finnish roots – has announced a EUR 15 million growth funding round led by VSquared Ventures. Tesi also participated in the round with its initial investment in Hedera, as did existing investors Helsana HealthInvest, Eyrir Venture Management, Inventure and Top Harvest.
Hedera, which has achieved scalable growth, is developing a new liquid biopsy test for cancer diagnostics and data solutions for its pharmaceutical clients.
“We want to accelerate the formation of innovation and competence clusters in Finland. Key personnel at Hedera have backgrounds in successful companies such as Blueprint Genetics and Kaiku Health. Building on these successes, the team is now well-positioned to develop new health tech know-how. I believe Hedera has the potential to become a strong European player alongside its U.S. counterparts,” says Joni Karsikas, Investment Director at Tesi.
In line with Tesi’s new investment strategy, the focus is increasingly on the scalable growth of tech companies. Health tech is one of the emphasized themes in Tesi’s investment activities, although the strategy is not limited to specific themes or industries.
Read more:
Additional information:
Joni Karsikas, Investment Director, Venture & Growth Investments
joni.karsikas@tesi.fi
+358 40 827 0395
Tesi (officially Finnish Industry Investment Ltd) is a state-owned, market-driven investment company that invests in venture capital and private equity funds and directly in Finnish startups and growth companies, and to new industrial scale businesses. tesi.fi | X (Twitter) | LinkedIn | Instagram | Bluesky | Threads | Newsletter